Proeklampsia- Eklampsia

7/23/2019 Proeklampsia- Eklampsia

http://slidepdf.com/reader/full/proeklampsia-eklampsia 1/36

!"#$%&'µ()'- *%&'µ()'

!"#$%&&" '()*+#%

,-./)#"0 12!"$(3/$.40 56$&$.40 7"&(8$9/:µ;)3 1<:&=&



+!*,-./01*/ 20.-.,.3*/

1+4/4/



ΥΠΕΡΤΑΣΙΚΕΣ

ΔΙΑΤΑΡΑΧΕΣ

ΚΥΗΣΗΣ

ΟΡΙΣΜΟΙ

>#?&$" 38-#/"9: – .!5. >140mmHg 6 .!7.>90mmHg 6 #8#)' 79':9:;<5%$='9 8"9; =6; %>656 ? 8"9; =6; 20$@7. %>656A %'9 $89µB;$9 µ$=C =#; =#%$=D.

7"#)*$.4 38-#/"9: – E8B"='56 %'=C =6 79C"%$9' =6A %>656A FG")A C&&' 5Eµ8=<µ'=' =6A 8"#$%&'µ()'A.

7#)(.6"µ@;" – #")H$='9 GA 6 'EI6µB;6 .! µ$=C =6; 20 $@7. %>656A (µ$ $I')"$56 =6; ="#J#@&'5=9%? ;D5# %'9 =9A 8#&>7Eµ$A %E?5$9A) %'9 F'"'%=6")H$='9 '8D:

• +8B"='56 (>140/90mmHg)

• K$E%Gµ'=#E")' (>1g ? >0.3g/24h)

•

L$;9%$EµB;# #)76µ' (+/-)4 &$E%Gµ'=#E")' %'9 6 E8B"='56 ;' $);'9 8'"#>5$A 5$ 2 79'7#F9%BA

$I$=C5$9A µ$ µ$5#79C5=6µ' >6 <"$A.



• 4 +8$"='59%? MD5#A $µJ';)H$='9 5=# 12-20% =G; %E?5$G; %'9 $);'9 E8$>NE;6 :9' 8$")8#E 18% =G; µ6="9%<; N';C=G;.

•

4 8"#$%&'µ()' $µJ';)H$='9 5=# 3-7% =G; 8"G=#=D%G; %'9 1-3% =G;

8#&E=D%G;

• *);'9 56µ';=9%DA '9=9#&#:9%DA 8'"C:#;='A 8$"9:$;;6=9%?A ;#56"D=6='A %'9

N;659µD=6='A, =D5# '8D =9A Cµ$5$A 5E;B8$9$A =6A E8$"='59%?A ;D5#E 5=# Bµ@"E# (E8#&$98Dµ$;6 $;7#µ?="9' ';C8=EI6, #&9:Cµ;9#, $;7#µ?="9#A NC;'=#A, %C), D5# %'9 '8D =#; 9'="#:$;? 8"DG"# =#%$=D, $I ’'9=)'A

$898&#%<; 8#E 8"#%'&$) 5=6 µ6=B"' ? 5=# Bµ@"E#.

• .; %'9 95=#"9%D 8"#O8C"F#E5'A E8B"='56A (F"D;9' E8B"='56) 8"#79'NB=$9 :9' ';C8=EI6 E8$"='59%?A ;D5#E %'9/? 5F$=9%<; µ$ 'E=? 79'='"'F<; 5=6;

%>656, 6 8'N#JE59#&#:)' %'9 6 ';=9µ$=<8956 $);'9 79'J#"$=9%BA %'9 :9’

'E=D $I$=CH#;='9 I$FG"95=C.



7#)(.6"µ@;"

• !#&E5E5=6µ'=9%? 79'='"'F? C:;G5=6A '9=9#&#:)'A, 8#E

F'"'%=6")H$='9 '8D E8B"='56, 79'='"':µB;6 ;$J"9%? &$9=#E":)'

8#E #76:$) 5$ 8"G=$P;#E")'.

• QA 8"G=$P;#E")' F'"'%=6")H$='9 6 8'"#E5)' &$E%<µ'=#A > 300mg

5$ 5E&&#:? #>"G; 24<"#E. *;'&&'%=9%C 79'8)5=G56 >8'"I6A &$E%<µ'=#A 8$"955D=$"# '8D B;' 5='E"D (+) 5$ 5=9% #>"G;.

•

4 8"#$%&'µ()' $µJ';)H$='9 µ$=C =6; 206 5Eµ8&6"GµB;6 $@7#µC7'

%E?5$GA 5$ :E;')%' µ$ JE59#&#:9%? .! 8"#6:#EµB;GA %'9 FG")A

8"#O8C"F#E5' ;$J"9%? @&C@6. .J#"C '8#%&$95=9%C =6;

';N"<89;6 %>656. /E;?NGA 8"<=' 5Eµ@');$9 6 E8B"='56 %'9 '%#&#EN$) 6 8"G=$P;#E")', '; %'9 5=# 10% =G; 8$"98=<5$G;

5Eµ@');$9 =# ';=)N$=#.



• R89' 8"#$%&'µ()': 5Eµµ$=#F? =G; ;$J"<; µ$ 8"G=$P;#E")'

• /#@'"? 8"#$%&'µ()': .!>160/110 µ$ 5#@'"? 8"G=$P;#E")' ? 56µ$)' 5#@'"?A @&C@6A #":C;G; (8"G=$P;#E")' >5gr 5$ 24 <"$A,

#&9:#E")' < 500ml 5$ 24 <"$A, 8;$Eµ#;9%D #)76µ',

µ9%"#'::$9#8'N6=9%? '9µD&E56, N"#µ@#8$;)', 68'=#%E=='"9%? @&C@6, $89:'5="9%D C&:#A, $:%$J'&9%BA ? #8=9%BA 79'='"'FBA,

$;7#µ?="9' E8#&$98Dµ$;6 ';C8=EI6 ? #&9:Cµ;9#) 5$ :E;')%$A µ$

8"#$%&'µ()'.



ΡΙ ΠΡΟΕΚΛ ΜΨΙ

ΟΡΙΣΜΟΣ

•

.!5. >140mmHg 6 .!7.>110mmHg 8'"#>5$A 5$ 279'7#F9%BA $I$=C5$9A µ$ µ$5#79C5=6µ' >6 <"$A.

• K$E%Gµ'=#E")' >5g /24G"#.

•

S&9:#E")' - <400mL /24<"$A ? %"$'=9;);6 #"#> >1.2 mg/dL

•

29'='"'FBA D"'56A ? 5E;$)7656A (5%#=<µ'=',%$J'&'&:)').

•

!;$Eµ#;9%D #)76µ' ? %EC;G56.

•

*89:C5="9' C&:6

•

T%8=G56 68'=9%?A &$9=#E":)'A (FG")A 5E;68C"F#E5' '9=)')

•

U"#µ@#%E=#8$;)' - <100,000/mm3



A.6"µ@;"

/Eµµ$=#F? =#E %$;="9%#> ;$E"9%#>

5E5=?µ'=#A µ$ '8#=B&$5µ' 58'5µ#>A 5$ '5N$;? µ$ 8"#$%&'µ()' 5=6; %>656, %'9

'8#E5)' C&&6A '9=)'A 58'5µ<;. 4 @&C@6 8#E 5Eµ@');$9 'J#"C 58'5µD =G;

$:%$J'&9%<; '::$)G;, 79C58'56 =#E

'9µ'=#$:%$J'&9%#> J"':µ#> %'9 $:%$J'&9%D #)76µ'



!,S*1K.VW0.

!.,.LSM*/ 10M2+MS+ •

!"<=6 %>656

•

4&9%)' µ6=B"'A (>40 ? <16 B=6)

• !#&>7Eµ6 %>656

•

S9%#:$;$9'%D 95=#"9%D

•

3"D;9' E8B"='56 (8"#E8C"F#E5')

• 3"D;9' ;$J"9%? ;D5#A

•

/'%F'"<76A 79'@?=6A

• .;=9JG5J#&98979%D 5>;7"#µ#

•

L#;)79# '::$9#='5);6A -235



•

BC&*#)µ) HELLP: />;7"#µ# 8#E F'"'%=6")H$='9 '8D '9µD&E56,

'EI6µB;$A 68'=9%BA 7#%9µ'5)$A %'9 F'µ6&C '9µ#8$=C&9'. /8C;9'

'&&C N';'=6JD"' 8'"'&&':? =6A 8"#$%&'µ()'A %'9 =6A $%&'µ()'A.

/E;';=C='9 5E;?NGA 5$ 8#&E=D%#EA %'9 5$ 6&9%)$A %>656A %C=G =G;

36 @7#µC7G;. /Eµ@');$9 5=# 20% =G; '5N$;<; µ$ 5#@'"?

8"#$%&'µ()'. -# 50% =G; '5N$;<; µ$ 5>;7"#µ# HELLP $µJ';)H$9 5#@'"? 8"#$%&'µ()', %'9 30% $µJ';)H$9 ?89' 8"#$%&'µ()'.

+8B"='56 7$; 5E;#7$>$9 =# 5>;7"#µ# 5=# 20% =G; '5N$;<;.



A7D7,E5AB – 5,DFD5G 7EHAD1

I1HAD1B 7HEA5,1!JD1B

•

EK'1,!ED – #)76µ' #8=9%?A N6&?A, '9µ#""':)' 'µJ9@&65="#$97#>A

• 1F17FALBMD5E – 8;$Eµ#;9%D #)76µ', 5>;7"#µ# ';'8;$E5=9%?A 7E5FB"9'A (ARDS)

•

G71H – E8#%C(9# '9µC=Gµ', "?I6 ?8'=#A.•

1D!E7EDGMD5E – 2*!, 5>;7"#µ# HELPP

•

5FB – 58'5µ#) , .**, $;7#%"';9'%? '9µ#""':)', $:%$J'&#8CN$9'

•

51HND1 – 1'"79'%? ';$8C"%$9' ('EI6µB;# µ$='J#"=)#)

•

71O5HA1B – 95F'9µ9%? 8':%"$'=)=97'

•

FAKHED – SI$)' ;$J"9%? ';$8C"%$9', 5G&6;'"9'%? ;B%"G56 •

!GMHE7,15ELFMD15G 5L5,EKEHD1 – IUGR, '8#%D&&656 8&'%#>;=', $µ@"EP%? 7E5FB"9', $µ@"EP%DA NC;'=#A.



ΡΕΙ ΠΡΟΕΚΛ ΜΨΙ

ΝΤΙΜΕΤΩΠΙΣΗ

•

*95':G:? 5=# ;#5#%#µ$)# – 8'"'%#&#>N656

•

-'%=9%? µB="656 .!, 5JE:µ<;, N$"µ#%"'5)'A %'9 95#H>:9# E:"<;.

• !&?"6A '9µ'=#&#:9%DA - @9#F6µ9%DA B&$:F#A %'9 B&$:F#A

86%=9%D=6='A.•

T&$:F#A #>"G; (&$E%Gµ'=#E")') – 5E&&#:? #>"G; 24<"#E.

•

*%=) µ656 =#E $µ@">#E – NST, U/S %'9 Doppler,

@9#JE59%D 8"#J)&.•

3#"?:656 ';=9-E8$"='59%<; '; F"$9CH$='9.



X.,*0. !,S*1K.VW0.

.M-0V*-Q!0/4

Y.,V.1*+-014 .LQL4 •

MgSO4 iv. ('; .!> 140/90mmHg)

.; .! 2 >110mmHg:• Hydralazine (NepresolR) 5-10mg iv %CN$

15’-30’.

•

Nifedipine (Adalat R) 10mg iv %CN$ 20’.

• Labetalol 20mg iv %CN$ 10’-20’.

•

L9' =# Bµ@"E#, F#"?:656: betamethasone 12mg/12h im.

*8958$>5=$ =#; =#%$=D.



X'"9C !"#$%&'µ()' & -#%$=DA

•

*897$);G56 $:%>#E;

• /#@'"D IUGR;

• Eµ@"E)%? 7E5FB"9';

•

-#%$=DA 5$ $IB&9I6;•

4&9%)' %>656A

>34$@7;

Επιλογή

μεθόδου

τοκετού

NAI

OXI • .; 6 :E;')%' $F$9 5='N$"#8#96N$) %'9

6 6&9%)' %>656A $);'9 <34$@7

• 1'N6µ$"9;? $%=) µ656 =6A $:%>#E

•

.8DJ'56 :9' F"?56 ';=9-E8$"='59%<;



X'"9C !"#$%&'µ()' & -#%$=DA

1'95'"9%? =#µ? D=';:•

*8$95D79' 58'5µ<; ? C&&# $8$):#;

• *µ@"EP%? 7E5FB"9'

•

.;<"9µ#A ="CF6&#A • /#@'"? 8"#G"D=6='



X.,*0. !,S*1K.VW0.

.M-0V*-Q!0/4

V*-. -SM -S1*-S

• /E;?NGA ='F$)' @$&=)G56 µ$=C =#; =#%$=D.

•

S %);7E;#A 58'5µ<; $);'9 µ$:'&>=$"#A =# 1#

24G"#.

• 3#"?:656 MgSO4 iv :9' 24<"$A

• !'"'%#&#>N656 $898B7G; MgSO4, .! %'9

'8#@#&?A #>"G;.

• T:%'9"6 ';':;<"956 89N';?A E8$"JD"=G56A

E:"<;.



*1K.VW0.

• *µJC;956 58'5µ<; 5=6; '5N$;?

(5E;?NGA $8) $7CJ#EA 8"#$%&'µ()'A).

• 1/2000 %E?5$9A (';$8=E:µB;$A F<"$A).

•

Z:;G5=6 '9=9#&#:)'.

•

4 .! $);'9 E(6&? (5=# 20% JE59#&#:9%?).

•

V8#"$) ;' 5Eµ@$) 8"9; (71%), %'=C =6 79C"%$9' ? µ$=C =#; =#%$=D.



*1K.VW0.

.M-0V*-Q!0/4

• 29'=?"656 '$"':G:#> (ABC).

• .;'""DJ656 $%%")5$G; (';'95N659#&.)

• !"D&6(6 ="'Eµ'=95µ#> =6A $:%>#E.

•

3#"?:656 MgSO4 iv

• .8#JE:? F#"?:656A 79'H$8Cµ6A ! ';'8;#?

• !"#:"'µµ'=95µDA =#%$=#> µD&9A 5='N$"#8#96N$)

6 %'=C5='56.! !"#5#F? 5=# 5>;7"#µ# HELPP (Hemolysis,

Elevated Liver enzymes, Low Platelets)



• *8'J? µ$ 8$"9@C&&#;, $89%#9;G;)'

• SIE:D;# µ$ µC5%'

•

Y&$@9%? :"'µµ?, $8$):#; 8&?"6A $":'5=6"9'%DA B&$:F#A

• NST F'µ6&? µ$='@&6=D=6=', DF9

$89='F>;5$9A, DF9 $89@"'7>;5$9A •

.! 200/120

• SE"#%'N$=?"'A, stick #>"G; +++

8"G=$);6



• /E;;$;D656 µ$ ';'95N659#&D:# %'9

F$9"#E":$)#

• .µ$56 µ$='J#"C :9' %'95'"9%? =#µ?

• Ht 29, WBC 8000, PLT 214000

• SGOT, SGPT<50 SE"9%D #I> 6.3

•

2 amp Nepresol/250ml iv, 30 mg Labetaloliv

• 3 amp MgSO4/250ml iv 5=C:76;

•

Fentanyl, Stedon iv



• L$;9%? ';'95N65)', 79'5G&?;G56

• *8$):#E5' %'95'"9%? =#µ?

•

.""$; 2200 :"µ, Apgar 9• Oxytocin, 1$J'&#58#");6 iv

• EBL 300 ml

•

1'&? 79#>"656



• .8#5G&?;G56 '5N$;#>A

• *;'"I6 $% ;B#E =#;9%#%&G;9%<; 58'5µ<;

•

*8$):#E5' $8';'79'5G&?;G56 • MgSO4 iv 4 g bolus, 1g/h 5=C:76;

• Nepresol 12.5 mg bolus, 50mg/250ml iv

•

V$='J#"C 5=6 V.Y .! 120/70, HR 106,SpO2 100



• V.Y 79'5G&6;GµB;6, µ6"9')' '"=6"9'%?

:"'µµ?, 5J':)=97'

• Nepresol, bolus Lasix,

• Flagyl, Voncon,

• LMWH, Human Albumin

•

K$>%Gµ' #>"G; 24/h 8,9 g• USS %'"79CA %J



• V$='J#"C 5=6; .;C;6(6 D3

• Sµ'&? µ$=$:F$9"6=9%? 8#"$)'

•

Norvasc 5mg x 2, LMWH, 1$J'&#58#");6 • *I9=?"9# D7 µ$ =# µG"D



*%&'µ()'

•

*;' ? 8'"'8C;G $8$95D79' 58'5µ<; 5$

5E5FB=956 µ$ 8"#$%&'µ()'

• 44% &#F$)', 18% 5=6 79C"%$9' =#%$=#>

• 5-20% $8';'&'µ@C;#;='9 8'"C =6

N$"'8$)'

•

2.6/10000 $:%Eµ#5>;$A (UK)•

M$E"#&#:9%BA $898&#%BA (1.2%) %<µ',

$5=9'%BA %9;6=9%BA @&C@$A, $:%$J'&9%D

'::$9'%D $8$95D79#, =>J&G56



•

-#;9%#%&G;9%#) 58'5µ#) C%"G; %'9

%$J'&?A

• 1EC;G56, 7C:%Gµ' :&<55'A, '%"C=$9'

#>"G;

• !&$9#(6J)' 5='µ'=#>; 5$ 1 [ &$8=D

•

*µ8$9")' 8#&> ="#µ'%=9%? :9' =6; B:%E#,=#EA 5E::$;$)A, =# 8"#5G89%D



.M-0V*-Q!0/4

XS4U*0.

+!S/-4,0\4 ABC

.$"':G:DA ."95=$"? 8&':)' NB56

SIE:D;# 5$

E(6&? "#?

IV :"'µµ? Screen PET

*K*L3S/ /!./VQM

2D56 $JD7#E MgSO4 4g IV5$ 20 &$8=C

/E;=?"656

MgSO4 1g/hr:9' 24 <"$A

+8#="#8? MgSO4 2g iv5$ 5 &$8=C



•

Collaborative Eclampsia Trial: ';G=$"D=6=' MgSO4B;';=9 79'H$8Cµ6A % J'9;E=#);6A 5=6; E8#="#8?

58'5µ<;

•

MAGPIE Trial: MgSO4 µ8#"$) ;' 8"#&C@$9 =6; $%&'µ()'

5$ 5#@'"? 8"#$%&'µ()'

• *% ;B#E E8#="#8? 58'5µ<;, 79'H$8Cµ6- J'9;E=#9;6,

N$9#8$;=D;6 ? 8"#8#JD&6 '8D ';'95N659#&D:#

• CT, MRI %"';)#E (89N';D '9µ#""':9%D $8$95D79#)



-#I9%D=6=' MgSO4

•

MgSO4 '8#@C&&$='9 '8#%&$95=9%C '8D =' ;$J"C

• /$ #&9:#E")', µB="656 $898B7G; % µ$)G56 7D56A

•

.8<&$9' $; =G @CN$9 ';=';'%&'5=9%<;, ';'8;$E5=9%? %'='5=#&?, ';'8;$E5=9%? ';'%#8?, ';'%#8? %'"79CA

• 1 g :&E%#;9%D '5@B5=9# iv (10 ml 79'&>µ'=#A 10%) $;=DA

10 &$8=<;

• Integrated review of side effects to the use of MgSO4 forPreeclampsia ans Eclampsia management



.;=9E8$"='59%? ':G:? 5$ 5#@'"?

8"#$%&'µ()'

•

.;$8'"%?A ';=9µ$=<8956 5E5=#&9%?A

E8B"='56A %>"9' µ$)HG; '9=)'

$;7#%"';9'%?A '9µ#""':)'A %'9 N';C=#E

=6A µ6=B"'A

• /E5=#&9%? E8B"='56 )56 ? >160 mm Hg

Cµ$56 B;'"I6 ';=9E8$"='59%?A ':G:?A

•

3$9"#%);6=# B;';=9 'E=Dµ'=# 89$5Dµ$="#

• +8$"='59%? $8)7"'56 &'"E::#5%D8656A

%'9 79'5G&?;G56A 5=6 :$;9%? ';'95N65)'



+7"'&'H);6 IV (1mg/ml)

2D56 $JD7#E 5 ml (5mg) 5$ 15 &$8=C

*8';C&6(6 '; .! >160/100 µ$=C '8D 20

min

2D56 5E;=?"656A *:FE56 5ml/hr

*897)GI6 79'5=#&9%? 90-100 mmHg

/E;?N6A 7D56 2-3 ml/hr

VB:95=6 7D56 B:FE56A 18 ml/hr

V$)G56 7D56A 5$ 5JE:µD >120/min



K'@6='&D&6 IV (5mg/ml)

2D56 $JD7#E 10 ml(50 mg) 5$ 2 &$8=C

*8';C&6(6 %CN$ 5&$8=C (max 4

7D5$9A)

2D56 5E;=?"656A B:FE56 4 ml/hr

298&'59'5µDA 7D56A %CN$ 30

&$8=C

VB:95=6 7D56 B:FE56A 32 ml/hr

K9:D=$"$A 8'"$;B":$9$A



05#H>:9# E:"<;

•

1);7E;#A E8$"JD"=G56A E:"<; %'9

8;$Eµ#;9%#> #97?µ'=#A 5$ 5#@'"?

8"#$%&'µ()'

•

!$"9#"95µDA F#"6:#>µ$;G; E:"<; 80 ml/

hr

• !=<56 %#"$5µ#> #IE:D;#E 5$ '"FDµ$;#

8;$Eµ#;9%D #)76µ'

• Y#E"#5$µ)76 iv 5$ $89µB;#E5' #&9:#E")'

• *8$µ@'=9%D monitoring



-# µG"D?

•

4 B:%E#A BF$9 '8D&E=6 8"#=$"'9D=6='

B;';=9 =#E µG"#>

• !"<=' 5='N$"#8#9$)='9 6 B:%E#A %'9

'%#&#EN$) # =#%$=DA

• 1'95'"9%? =#µ? µ$ $895%&6")79#

•

.8#JE:? $":#µ6=");6A

• !"#$ %&'()&*( +$, )'-&./( µ 0*(, -

+-.&+",





Proeklampsia- Eklampsia

Documents